argenx SE to Announce Q4 Earnings on February 26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ARGX?
Source: seekingalpha
- Earnings Announcement: argenx SE is set to release its Q4 2023 earnings on February 26 before market open, with consensus EPS estimated at $6.20 and revenue projected at $1.3 billion, reflecting a robust 76.4% year-over-year growth potential in the biopharmaceutical sector.
- Performance Revisions: Over the past three months, EPS estimates have seen 7 upward revisions and 6 downward adjustments, while revenue estimates experienced 8 upward and 9 downward revisions, indicating market divergence regarding the company's future performance, which could impact investor confidence.
- Market Focus: The upcoming earnings report is a focal point for investors, especially against the backdrop of the FDA's priority review of argenx's Vyvgart label expansion, with market expectations high for future product line growth.
- Leadership Transition: argenx recently announced a CEO transition, which may influence the company's strategic direction and market performance, prompting investors to monitor how the new leadership team will drive future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARGX
Wall Street analysts forecast ARGX stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 766.920
Low
858.00
Averages
1048
High
1317
Current: 766.920
Low
858.00
Averages
1048
High
1317
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
- Strong Performance: Argenx reported Q4 earnings of $8.02 per share, exceeding the consensus estimate of $6.02, which underscores the company's robust profitability and enhances investor confidence.
- Significant Sales Growth: Sales surged from $761.2 million to $1.32 billion, surpassing the expected $1.29 billion, reflecting strong demand for VYVGART and the success of the company's sales strategies.
- Expanded Patient Reach: The number of patients treated with VYVGART globally has reached 19,000, indicating the company's growing influence in the ocular myasthenia gravis (oMG) market and strengthening its competitive position in related disease areas.
- R&D Progress: Argenx has made substantial advancements across multiple development programs, particularly with the successful launch of the pre-filled syringe, marking a strategic expansion in the chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis (gMG) sectors.
See More
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
- Clinical Trial Success: Argenx's ADAPT OCULUS study demonstrated that VYVGART led to a mean improvement of 4.04 points in Myasthenia Impairment Index scores for ocular myasthenia gravis patients, significantly outperforming the placebo group's 1.99 points with a p-value of 0.012, indicating a substantial unmet need in treatment.
- Strong Safety Profile: The safety profile of VYVGART remained consistent with previous studies, with no new safety concerns identified, and patients experienced marked reductions in key ocular symptoms such as diplopia and ptosis, enhancing its competitive edge in the market.
- Robust Sales Performance: Argenx reported Q4 earnings of $8.02 per share, exceeding the consensus estimate of $6.02, with sales soaring from $761.2 million to $1.32 billion, surpassing the expected $1.29 billion, reflecting strong market demand.
- Optimistic Market Outlook: Analyst William Blair stated that these positive results will solidify VYVGART as the preferred biologic therapy for all MG patients and continue to increase its first-line biologic market share, indicating significant growth potential ahead.
See More
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
- Successful Phase 3 Trial: Argenx announced positive results for its eye disease treatment Vyvgart in Phase 3 trials, demonstrating significant efficacy and further solidifying its market position in ophthalmology.
- Significant Sales Surge: Vyvgart's sales surged over 70% year-over-year, reflecting strong market demand for the drug and establishing a solid foundation for future revenue growth for the company.
- Earnings Beat Expectations: The company's earnings exceeded market expectations, indicating that its effective strategies in research and marketing are yielding results, thereby boosting investor confidence.
- Strategic Market Expansion: Following Vyvgart's success, Argenx plans to further expand its product line in the ophthalmology sector, aiming to enhance overall competitiveness through continuous innovation and market penetration.
See More
argenx SE Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: argenx SE reported a Q4 GAAP EPS of $8.02, exceeding expectations by $1.70, indicating a significant improvement in profitability and reflecting the company's competitive position in the market.
- Revenue Growth: Q4 2025 revenue reached $1.29 billion, a 75% year-over-year increase, although it missed expectations by $10 million, suggesting challenges in the company's rapid expansion.
- Product Sales Performance: VYVGART's net sales for 2025 were $1.3 billion, with annual sales of $4.2 billion, significantly up from $0.7 billion and $2.2 billion in 2024, demonstrating strong market demand.
- FDA Review Progress: The label expansion application for VYVGART is undergoing FDA priority review, and if approved, it will further drive sales growth and enhance the company's market position.
See More
argenx Reports $4.2 Billion in 2025 Net Sales, Achieving First Year of Profitability
- Strong Financial Performance: argenx achieved global product net sales of $4.2 billion in 2025, reflecting a remarkable 90% year-over-year growth, with fourth-quarter sales reaching $1.3 billion, indicating robust market expansion and enhanced profitability.
- First Year of Operating Profitability: The company reported $1.1 billion in operating income for 2025, marking its first year of profitability, which underscores successful cost management and market penetration, thereby boosting investor confidence.
- Product Line Expansion: The label expansion of VYVGART is supported by positive results from the ADAPT SERON and OCULUS studies, with a PDUFA target action date of May 10, 2026, for the anti-AChR antibody-negative gMG filing, reinforcing its leadership in the autoimmune disease sector.
- Future Strategic Goals: The company aims to treat 50,000 patients by 2030 and plans to advance five pipeline candidates into Phase 3 development, demonstrating a strong commitment to long-term growth and strategic market expansion.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
- Strong Performance: Argenx reported Q4 earnings of $8.02 per share, exceeding the consensus estimate of $6.02, which underscores the company's robust profitability and enhances investor confidence.
- Significant Sales Growth: Sales surged from $761.2 million to $1.32 billion, surpassing the expected $1.29 billion, reflecting strong demand for VYVGART and the success of the company's sales strategies.
- Expanded Patient Reach: The number of patients treated with VYVGART globally has reached 19,000, indicating the company's growing influence in the ocular myasthenia gravis (oMG) market and strengthening its competitive position in related disease areas.
- R&D Progress: Argenx has made substantial advancements across multiple development programs, particularly with the successful launch of the pre-filled syringe, marking a strategic expansion in the chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis (gMG) sectors.
See More
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
- Clinical Trial Success: Argenx's ADAPT OCULUS study demonstrated that VYVGART led to a mean improvement of 4.04 points in Myasthenia Impairment Index scores for ocular myasthenia gravis patients, significantly outperforming the placebo group's 1.99 points with a p-value of 0.012, indicating a substantial unmet need in treatment.
- Strong Safety Profile: The safety profile of VYVGART remained consistent with previous studies, with no new safety concerns identified, and patients experienced marked reductions in key ocular symptoms such as diplopia and ptosis, enhancing its competitive edge in the market.
- Robust Sales Performance: Argenx reported Q4 earnings of $8.02 per share, exceeding the consensus estimate of $6.02, with sales soaring from $761.2 million to $1.32 billion, surpassing the expected $1.29 billion, reflecting strong market demand.
- Optimistic Market Outlook: Analyst William Blair stated that these positive results will solidify VYVGART as the preferred biologic therapy for all MG patients and continue to increase its first-line biologic market share, indicating significant growth potential ahead.
See More
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
- Successful Phase 3 Trial: Argenx announced positive results for its eye disease treatment Vyvgart in Phase 3 trials, demonstrating significant efficacy and further solidifying its market position in ophthalmology.
- Significant Sales Surge: Vyvgart's sales surged over 70% year-over-year, reflecting strong market demand for the drug and establishing a solid foundation for future revenue growth for the company.
- Earnings Beat Expectations: The company's earnings exceeded market expectations, indicating that its effective strategies in research and marketing are yielding results, thereby boosting investor confidence.
- Strategic Market Expansion: Following Vyvgart's success, Argenx plans to further expand its product line in the ophthalmology sector, aiming to enhance overall competitiveness through continuous innovation and market penetration.
See More
argenx SE Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: argenx SE reported a Q4 GAAP EPS of $8.02, exceeding expectations by $1.70, indicating a significant improvement in profitability and reflecting the company's competitive position in the market.
- Revenue Growth: Q4 2025 revenue reached $1.29 billion, a 75% year-over-year increase, although it missed expectations by $10 million, suggesting challenges in the company's rapid expansion.
- Product Sales Performance: VYVGART's net sales for 2025 were $1.3 billion, with annual sales of $4.2 billion, significantly up from $0.7 billion and $2.2 billion in 2024, demonstrating strong market demand.
- FDA Review Progress: The label expansion application for VYVGART is undergoing FDA priority review, and if approved, it will further drive sales growth and enhance the company's market position.
See More
argenx Reports $4.2 Billion in 2025 Net Sales, Achieving First Year of Profitability
- Strong Financial Performance: argenx achieved global product net sales of $4.2 billion in 2025, reflecting a remarkable 90% year-over-year growth, with fourth-quarter sales reaching $1.3 billion, indicating robust market expansion and enhanced profitability.
- First Year of Operating Profitability: The company reported $1.1 billion in operating income for 2025, marking its first year of profitability, which underscores successful cost management and market penetration, thereby boosting investor confidence.
- Product Line Expansion: The label expansion of VYVGART is supported by positive results from the ADAPT SERON and OCULUS studies, with a PDUFA target action date of May 10, 2026, for the anti-AChR antibody-negative gMG filing, reinforcing its leadership in the autoimmune disease sector.
- Future Strategic Goals: The company aims to treat 50,000 patients by 2030 and plans to advance five pipeline candidates into Phase 3 development, demonstrating a strong commitment to long-term growth and strategic market expansion.
See More
